Joincare Pharmaceutical Group Industry Co.,Ltd. (SHA:600380)
10.61
+0.20 (1.92%)
Apr 22, 2025, 2:45 PM CST
SHA:600380 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 15,492 | 16,522 | 17,013 | 15,747 | 13,446 | Upgrade
|
Other Revenue | 127.91 | 124.63 | 130.02 | 157.06 | 75.73 | Upgrade
|
Revenue | 15,619 | 16,646 | 17,143 | 15,904 | 13,522 | Upgrade
|
Revenue Growth (YoY) | -6.17% | -2.90% | 7.79% | 17.62% | 12.87% | Upgrade
|
Cost of Revenue | 6,099 | 6,608 | 6,380 | 5,778 | 4,944 | Upgrade
|
Gross Profit | 9,521 | 10,039 | 10,763 | 10,126 | 8,577 | Upgrade
|
Selling, General & Admin | 4,836 | 5,368 | 5,944 | 5,966 | 4,898 | Upgrade
|
Research & Development | 1,435 | 1,662 | 1,742 | 1,397 | 1,072 | Upgrade
|
Other Operating Expenses | 155.49 | 177.21 | 196.72 | 180.8 | 161.03 | Upgrade
|
Operating Expenses | 6,431 | 7,224 | 7,885 | 7,553 | 6,136 | Upgrade
|
Operating Income | 3,090 | 2,815 | 2,877 | 2,572 | 2,442 | Upgrade
|
Interest Expense | -123.26 | -146.73 | -139.02 | -90.28 | -35.69 | Upgrade
|
Interest & Investment Income | 481.67 | 611.73 | 451.45 | 263.85 | 385.8 | Upgrade
|
Currency Exchange Gain (Loss) | 22.87 | 27.25 | 104.46 | -2.74 | -62.35 | Upgrade
|
Other Non Operating Income (Expenses) | -17.81 | -7.69 | -9.62 | -4.89 | -7.72 | Upgrade
|
EBT Excluding Unusual Items | 3,453 | 3,300 | 3,285 | 2,738 | 2,722 | Upgrade
|
Gain (Loss) on Sale of Investments | -17.5 | -25.42 | -76.26 | -23.51 | 10.22 | Upgrade
|
Gain (Loss) on Sale of Assets | 45.26 | -0.17 | -0.71 | 24.04 | -7.19 | Upgrade
|
Asset Writedown | -30.09 | -3.27 | -31.51 | -8.25 | -4.18 | Upgrade
|
Other Unusual Items | 123.81 | 194.75 | 280.06 | 221.66 | 229.61 | Upgrade
|
Pretax Income | 3,575 | 3,466 | 3,456 | 2,952 | 2,950 | Upgrade
|
Income Tax Expense | 592.14 | 614.54 | 561.8 | 339.48 | 371.69 | Upgrade
|
Earnings From Continuing Operations | 2,983 | 2,851 | 2,894 | 2,613 | 2,578 | Upgrade
|
Minority Interest in Earnings | -1,596 | -1,408 | -1,392 | -1,284 | -1,458 | Upgrade
|
Net Income | 1,387 | 1,443 | 1,503 | 1,328 | 1,120 | Upgrade
|
Net Income to Common | 1,387 | 1,443 | 1,503 | 1,328 | 1,120 | Upgrade
|
Net Income Growth | -3.90% | -3.99% | 13.12% | 18.57% | 25.28% | Upgrade
|
Shares Outstanding (Basic) | 1,874 | 1,898 | 1,894 | 1,935 | 1,948 | Upgrade
|
Shares Outstanding (Diluted) | 1,874 | 1,898 | 1,897 | 1,937 | 1,956 | Upgrade
|
Shares Change (YoY) | -1.30% | 0.07% | -2.07% | -0.97% | 0.76% | Upgrade
|
EPS (Basic) | 0.74 | 0.76 | 0.79 | 0.69 | 0.58 | Upgrade
|
EPS (Diluted) | 0.74 | 0.76 | 0.79 | 0.69 | 0.57 | Upgrade
|
EPS Growth | -2.63% | -4.06% | 15.52% | 19.73% | 24.33% | Upgrade
|
Free Cash Flow | 2,657 | 2,799 | 2,830 | 1,042 | 2,195 | Upgrade
|
Free Cash Flow Per Share | 1.42 | 1.47 | 1.49 | 0.54 | 1.12 | Upgrade
|
Dividend Per Share | 0.200 | 0.180 | 0.180 | 0.150 | 0.150 | Upgrade
|
Dividend Growth | 11.11% | - | 20.00% | - | -6.25% | Upgrade
|
Gross Margin | 60.96% | 60.31% | 62.78% | 63.67% | 63.43% | Upgrade
|
Operating Margin | 19.78% | 16.91% | 16.78% | 16.18% | 18.06% | Upgrade
|
Profit Margin | 8.88% | 8.67% | 8.77% | 8.35% | 8.29% | Upgrade
|
Free Cash Flow Margin | 17.01% | 16.81% | 16.51% | 6.55% | 16.23% | Upgrade
|
EBITDA | 3,866 | 3,837 | 3,683 | 3,167 | 2,989 | Upgrade
|
EBITDA Margin | 24.75% | 23.05% | 21.48% | 19.91% | 22.10% | Upgrade
|
D&A For EBITDA | 775.67 | 1,022 | 805.34 | 594.45 | 546.91 | Upgrade
|
EBIT | 3,090 | 2,815 | 2,877 | 2,572 | 2,442 | Upgrade
|
EBIT Margin | 19.78% | 16.91% | 16.78% | 16.18% | 18.06% | Upgrade
|
Effective Tax Rate | 16.56% | 17.73% | 16.25% | 11.50% | 12.60% | Upgrade
|
Revenue as Reported | 15,619 | 16,646 | 17,143 | 15,904 | 13,522 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.